3 Promising Penny Stocks With Market Caps Over $100M

Over the last 7 days, the market has risen 1.9%, and it is up 24% over the last 12 months, with earnings expected to grow by 15% per annum over the next few years. Penny stocks may be a throwback term, but they still represent opportunities for growth at lower price points when backed by strong balance sheets and solid fundamentals. In this article, we explore several high-quality penny stocks that stand out as hidden gems with potential for impressive returns.

Top 10 Penny Stocks In The United States

Name Share Price Market Cap Financial Health Rating ATRenew (RERE) $4.42 $1.05B ★★★★★★ LexinFintech Holdings (LX) $2.25 $360.08M ★★★★★★ FinVolution Group (FINV) $4.94 $1.24B ★★★★★☆ Tuniu (TOUR) $0.7333 $88.47M ★★★★★★ Information Services Group (III) $3.11 $183.07M ★★★★★★ Golden Growers Cooperative (GGRO.U) $5.00 $77.45M ★★★★★★ Niagen Bioscience (NAGE) $4.38 $362.72M ★★★★★★ Cricut (CRCT) $4.00 $825.95M ★★★★★★ LifeVantage (LFVN) $4.25 $53.78M ★★★★★★ Village Farms International (VFF) $2.74 $316.54M ★★★★★★

Click here to see the full list of 360 stocks from our US Penny Stocks screener.

We're going to check out a few of the best picks from our screener tool.

Drilling Tools International

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Drilling Tools International Corporation designs, engineers, manufactures, and rents tools for horizontal and directional drilling operations across North America, Europe, the Middle East, and Asia-Pacific with a market cap of approximately $150.95 million.

Operations: Drilling Tools International generates revenue from the Eastern Hemisphere at $23.48 million and the Western Hemisphere at $148.57 million.

Market Cap: $150.95M

Drilling Tools International Corporation, with a market cap of approximately US$150.95 million, has shown mixed financial performance. Despite reporting a net income of US$1.22 million for Q4 2025 compared to a loss the previous year, it remains unprofitable overall with a full-year net loss of US$3.76 million in 2025. The company is trading at an attractive value relative to its estimated fair value and peers but faces challenges such as high volatility and insufficient coverage of interest payments by EBIT (1.3x). Recent strategic moves include share buybacks and board refreshment efforts aimed at aligning with long-term growth objectives.

Unlock comprehensive insights into our analysis of Drilling Tools International stock in this financial health report. Gain insights into Drilling Tools International's outlook and expected performance with our report on the company's earnings estimates.DTI Debt to Equity History and Analysis as at Apr 2026

Autolus Therapeutics

Simply Wall St Financial Health Rating: ★★★★☆☆

Story Continues

Overview: Autolus Therapeutics plc is a clinical-stage biopharmaceutical company focused on developing T cell therapies for cancer and autoimmune diseases, with a market cap of approximately $367.28 million.

Operations: Autolus Therapeutics currently does not report any revenue segments.

Market Cap: $367.28M

Autolus Therapeutics, with a market cap of US$367.28 million, is navigating the challenges typical of a clinical-stage biopharmaceutical firm. Despite being pre-revenue until recently, it posted significant revenue growth in 2025 to US$75.39 million from just US$10.12 million the previous year. However, its net loss widened to US$287.53 million for the year, reflecting ongoing operational and development costs associated with its T cell therapies pipeline. The company's financial position shows short-term assets exceeding both short and long-term liabilities, though it faces less than a year of cash runway at current burn rates without additional financing or revenue improvements.

Click here and access our complete financial health analysis report to understand the dynamics of Autolus Therapeutics. Learn about Autolus Therapeutics' future growth trajectory here.AUTL Debt to Equity History and Analysis as at Apr 2026

Genius Sports

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Genius Sports Limited offers technology-driven products and services to the sports, sports betting, and sports media sectors globally, with a market cap of approximately $1.12 billion.

Operations: The company generates revenue primarily from its data processing segment, which amounted to $669.49 million.

Market Cap: $1.12B

Genius Sports, with a market cap of US$1.12 billion, is leveraging its Moment Engine to transform live sports into real-time advertising opportunities, integrating with key partners like DIRECTV and Publicis Sports. Despite being unprofitable, the company has reduced losses over five years and maintains a stable cash runway exceeding three years due to positive free cash flow. Recent legal challenges involve allegations related to addictive microbetting practices in collaboration with major platforms like DraftKings and FanDuel. Genius Sports' strategic partnerships enhance its data-driven media capabilities across major sporting events such as the Super Bowl and NBA Finals.

Jump into the full analysis health report here for a deeper understanding of Genius Sports. Examine Genius Sports' earnings growth report to understand how analysts expect it to perform.GENI Revenue & Expenses Breakdown as at Apr 2026

Seize The Opportunity

Reveal the 360 hidden gems among our US Penny Stocks screener with a single click here. Searching for a Fresh Perspective? We've found 15 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include DTIAUTL and GENI.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments